Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Zevra Therapeutics Inc shares valued at $45,825 were purchased by Bode John B on Aug 19 ’25. At $9.16 per share, Bode John B acquired 5,000 shares. The insider’s holdings grew to 45,000 shares worth approximately $0.43 million following the completion of this transaction.
Also, Thompson Rahsaan sold 24,000 shares, netting a total of over 221,004 in proceeds. Following the sale of shares at $9.21 each, the insider now holds 42,666 shares.
Before that, RAHSAAN THOMPSON had added 24,000 shares to its account. In a trade valued at $223,920, the Officer bought Zevra Therapeutics Inc shares for $9.33 each.
As published in their initiating research note from H.C. Wainwright on July 02, 2025, Zevra Therapeutics Inc [ZVRA] has been a Buy and the price target has been revised to $26. As of October 07, 2024, Guggenheim has initiated its “Buy” rating for ZVRA. Earlier on September 24, 2024, Maxim Group resumed its rating. Their recommendation was “a Buy” for ZVRA stock.
Analyzing ZVRA Stock Performance
On last trading session, Zevra Therapeutics Inc [NASDAQ: ZVRA] rose 2.48% to $9.51. The stock’s lowest price that day was $9.35, but it reached a high of $10.1495 in the same session. During the last five days, there has been a surge of approximately 6.85%. Over the course of the year, Zevra Therapeutics Inc shares have jumped approximately 34.32%. Shares of the company reached a 52-week high of $13.16 on 07/15/25 and a 52-week low of $6.19 on 04/09/25.
Support And Resistance Levels for Zevra Therapeutics Inc (ZVRA)
According to the 24-hour chart, there is a support level at 9.19, which, if violated, would cause prices to drop to 8.87. In the upper region, resistance lies at 9.99. The next price resistance is at 10.47. RSI (Relative Strength Index) is 39.89 on the 14-day chart, showing neutral technical sentiment.
Is Zevra Therapeutics Inc subject to short interest?
Stocks of Zevra Therapeutics Inc saw a sharp steep in short interest on 2025-07-31 dropping by -0.35 million shares to 4.64 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 4.99 million shares. A decline of -7.58% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.44 of the overall float, the days-to-cover ratio (short ratio) decline to 3.44.
Which companies own the most shares of Zevra Therapeutics Inc (ZVRA)?
In terms of Zevra Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 115.52% from the previous closing price of $9.28. Analysts anticipate Zevra Therapeutics Inc stock to reach 22 by 2025, with the lowest price target being 18. In spite of this, 7 analysts ranked Zevra Therapeutics Inc stock as Buy at the end of 2025. On September 24, 2024, JMP Securities assigned a price target of “a Mkt outperform” to the stock and initiated coverage with a $17.
